FDA Logo links to FDA home page Skip Navigation
U.S. Food and Drug Administration
 HHS Logo links to Department of Health and Human Services website
Skip navigationFDA Home Page | Dockets Home Page | Dockets Contacts and Location | Operating Status | Item Code Definitions
horizonal rule
Dockets Management

Up | AC Home Page

Food and Drug Administration

Peripheral and Central Nervous System Drugs Advisory Committee

May 17, 2006

Slides Sponsor Presentations    

Exelon® (rivastigmine) Introduction and Regulatory Overview, Martina Stuck, PhD, Novartis Pharmaceuticals Corporation (ppt) (htm)

The Neuropathology of Parkinson’s Disease with Dementia, James B. Leverenz, MD, University of Washington School of Medicine (ppt) (htm)


Parkinson’s disease Dementia (PDD) :  A Clinical Perspective, Howard Feldman, MMCM, FRCP (C),University of British Columbia, Canada (ppt) (htm)

Clinical Summary, Clive Ballard, MD, University of London (ppt) (htm)

Rationale for Indication of Parkinson’s Disease Dementia (PDD) & Study Design, Roger Lane, MD, MPH, Novartis Pharmaceuticals Corporation (ppt) (htm)

Express Results, Sibel Tekin, MD, Novartis Pharmaceuticals Corporation (ppt) (htm)

Benefits-Risk Assessment, Murat Emre, MD, Istanbul University, Turkey (ppt) (htm)

 

Exelon® (rivastigmine) PDD Indication Regulatory Considerations , Martina Stuck, PhD, Novartis Pharmaceuticals Corporation (ppt) (htm)

 

Sponsor Supportive Slides (ppt) (htm)

Questions (ppt) (htm)

Page last updated May 24, 2006 kkhorizonal rule
Dockets Home Page | Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

FDA/Dockets Management